Tosymra (sumatriptan; Upsher Smith Laboratories) Nasal Spray is now available for the acute treatment of migraine with or without aura in adults.
Researchers have proposed an update to the International Classification of Headache Disorders-3 criteria for headache attributed to transient ischemic attacks.
Fremanezumab, administered once monthly or once quarterly, is associated with greater reductions in monthly average migraine days than placebo in patients with difficult-to-treat migraine who did not respond to ≥2 of 4 classes of migraine preventative medications.
Telemedicine delivered over 1 year to patients with severe migraine-related disability was comparable to in-office visits for improving migraine disability, number of headache days, and average headache severity at 12 months.
A study highlights predictors of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA).
Migraines are a significant risk factor for Alzheimer disease (AD) and all-cause dementia.
Investigators analyzed whether high LDL-C causally relates to risk for retinopathy, neuropathy, chronic kidney disease, and peripheral artery disease in the general population.
Biofeedback may effectively improve headache and urinary incontinence related to prostatectomy.
CNTX-6016, a highly-selective cannabinoid receptor type 2 agonist, was found to provide adequate analgesia in preclinical models of neuropathic pain.
Women with migraine are more likely to present with worse performance of the cervical muscles, both in force production and muscle activity, compared with women without migraine.